CLC-3 Cl- channel-mediated invasion and migration of human ovarian cancer cells

Objectives: To investigate the potential role of CLC-3, a member of the voltage-gated chloride channel (CLC) superfamily, in invasion and migration of ovarian cancer cell line SKOV3. Materials and Methods: CLC-3 antisense oligonucleotides were transfected into ovarian cancer cell line SKOV3, and its effects on cell invasion and migration were analyzed by using Transwell chamber assay and wound healing assay in vitro. The efficiency of CLC-3 antisense was determined with RT-PCR and Western blotting. The protein concentrations of matrix metalloproteinase (MMP)-2, MMP-9, and vascular endothelial growth factor (VEGF) were determined using ELISA kits. Cell volume measurements were performed. Results: Studies in vitro revealed that the CLC-3 antisense inhibited invasion and migration of ovarian cancer cell line SKOV3. CLC-3 antisense treatment decreased protein levels of MMP-2, MMP-9, and VEGF in culture medium of SKOV3 cells. In addition, the authors found that the capability for regulatory volume decrease (RVD) was much attenuated in SKOV3 cells transfected with CLC-3 antisense. Conclusions: These results strongly suggest that CLC-3 may get involved in proliferation, invasion, and migration of ovarian cancer cells and thus may be a useful therapeutic target.

Chloride channels; Invasion; Migration; Ovarian cancer.

[1] Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al.: “Cancer statistics, 2005”. CA. Cancer. J. Clin., 2005, 55, 10.

[2] Naora H., Montell D.J.: “Ovarian cancer metastasis: integrating insights from disparate model organisms”. Nat. Rev. Cancer, 2005, 5, 355.

[3] Li M., Wang B., Lin W.: “Cl-channel blockers inhibit cell proliferation and arrest the cell cycle of human ovarian cancer cells”. Eur. J. Gynaecol. Oncol., 2008, 29, 267.

[4] Li M., Wang Q., Lin W., Wang B.: “Regulation of ovarian cancer cell adhesion and invasion by Cl- channels”. Int. J. Gynecol. Cancer, 2009, 19, 526.

[5] Li M., Wu D.B., Wang J.: “Effects of volume-activated chloride channels on the invasion and migration of human endometrial cancer cells”. Eur. J. Gynaecol. Oncol., 2013, 34, 60.

[6] Olsen M.L., Schade S., Lyons S.A., Amaral M.D., Sontheimer H.: “Expression of voltage-gated chloride channels in human glioma cells”. J. Neurosci., 2003, 23, 5572.

[7] Hermoso M., Satterwhite C.M., Andrade Y.N., Hidalgo J., Wilson S.M., Horowitz B., Hume J.R.: “ClC-3 is a fundamental molecular component of volume-sensitive outwardly rectifying Cl- channels and volume regulation in HeLa cells and Xenopus laevis oocytes”. J. Biol. Chem., 2002, 277, 40066.

[8] Wang G.X., Hatton W.J., Wang G.L., Zhong J., Yamboliev I., Duan D., Hume J.R.: “Functional effects of novel anti-ClC-3 antibodies on native volume-sensitive osmolyte and anion channels in cardiac and smooth muscle cells”. Am. J. Physiol. Heart. Circ. Physiol., 2003, 285, H1453.

[9] Chen L.X., Zhu L.Y., Jacob T.J., wang L.W.: “Roles of volume-activated Cl- currents and regulatory volume decrease in the cell cycle and proliferation in nasopharyngeal carcinoma cells”. Cell. Prolif., 2007, 40, 253.

[10] Ransom C.B., O'Neal J.T., Sontheimer H.: “Volume-activated chloride currents contribute to the resting conductance and invasive migration of human glioma cells”. J. Neurosci., 2001, 21, 7674.

[11] Mao J., Wang L., Fan A., Wang J., Xu B., Jacob T.J., Chen L.: “Blockage of volume-activated chloride channels inhibits migration of nasopharyngeal carcinoma cells”. Cell. Physiol. Biochem., 2007, 19, 249.

[12] Wang L., Chen L., Jacob T.J.: “The role of ClC-3 in volume-activated chloride currents and volume regulation in bovine epithelial cells demonstrated by antisense inhibition”. J. Physiol., 2000, 524, 63.

[13] Duffy S.M., Leyland M.L., Conley E.C., Bradding P.: “Voltage-dependent and calcium-activated ion channels in the human mast cell line HMC-1”. J. Leukoc. Biol., 2001, 70, 233.

[14] Davidson B., Goldberg I., Gotlieb W.H., Kopolovic J., Ben-Baruch G., Nesland J.M. et al.: “High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma”. Clin. Exp. Metastasis, 1999, 17, 799.

[15] Belotti D., Paganoni P., Manenti L., Garofalo A., Marchini S., Taraboletti G., Giavazzi R.: “Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation”. Cancer. Res., 2003, 63, 5224.

[16] Hara-Chikuma M., Yang B., Sonawane N.D., Sasaki S., Uchida S., Verkman A.S.: “ClC-3 chloride channels facilitate endosomal acidification and chloride accumulation”. J. Biol. Chem., 2005, 280, 1241.

[17] Dai Y.P., Bongalon S., Hatton W.J., Hume J.R., Yamboliev I.: “ClC- 3 chloride channel is upregulated by hypertrophy and inflammation in rat and canine pulmonary artery”. Br. J. Pharmacol., 2005, 145,5.

[18] Lemonnier L., Lazarenko R., Shuba Y., Thebault S., Roudbaraki M., Lepage G. et al.: “Alterations in the regulatory volume decrease (RVD) and swelling-activated Cl- current associated with neuroendocrine differentiation of prostate cancer epithelial cells”. Endocr. Relat. Cancer, 2005, 12, 335.

[19] Yamamoto-Mizuma S., Wang G.X., Liu L.L., Schegg K., Hatton W.J., Duan D. et al.: “Altered properties of volume-sensitive osmolyte and anion channels (VSOACs) and membrane protein expression in cardiac and smooth muscle myocytes from Clcn3-/- mice”. J. Physiol., 2004, 557, 439.

[20] Weylandt K.H., Valverde M.A., Nobles M., Raguz S., Amey J.S., Diaz M. et al.: “Human ClC-3 is not the swelling-activated chloride channel involved in cell volume regulation”. J. Biol. Chem., 2001, 276, 17461.

[21] Lang F., Busch G.L., Ritter M., Völkl H., Waldegger S., Gulbins E., Häussinger D.: “Functional significance of cell volume regulatory mechanisms”. Physiol. Rev., 1998, 78, 247.

[22] Mignatti P., Rifkin D.B.: “Biology and biochemistry of proteinases in tumor invasion”. Physiol. Rev., 1993, 73, 161.

[23] Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak HF.: “Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid”. Science, 1983, 219, 983.

[24] Manenti L., Paganoni P., Floriani I., Landoni F., Torri V., Buda A. et al.: “Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma”. Eur. J. Cancer, 2003, 39, 1948.

[25] Yabushita H., Shimazu M., Noguchi M., Kishida T., Narumiya H., Sawaguchi K., Noguchi M.: “Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer”. Oncol. Rep., 2003, 10, 89.